Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia

Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in... Patients with treatment-resistant schizophrenia pose a major challenge to caregivers since only clozapine is documented as having superior efficacy in this population. Although olanzapine is similar to clozapine in structure and receptor profile, it has not been proven to have superior efficacy for this patient group. Nonetheless, olanzapine is being increasingly used in higher doses as clinicians attempt to find a more effective and tolerable therapy for refractory patients. Furthermore, there are little data comparing olanzapine and clozapine in this population. Thirteen patients participated in a randomized double-blind 16-week crossover study of clozapine therapy (450 mg/day) compared to high doses of olanzapine (50 mg/day). No patients on olanzapine responded while 20% responded to clozapine treatment. Olanzapine patients tended to experience higher rates of anticholinergic effects such as dry mouth (80 vs. 20%) and blurry vision (40 vs. 0%). Clozapine-treated patients had higher rates of sialorrhea (80 vs. 10%), sweating (50 vs. 10%), dyspepsia (70 vs. 30%), and lethargy (90 vs. 60%). Neither treatment was associated with significant akathisia. Liver enzyme elevation and lipids were higher with clozapine treatment. Mean weight gain in the initial 8 weeks was 3.4 kg for olanzapine and 1.2 kg for clozapine. High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/adverse-effects-and-laboratory-parameters-of-high-dose-olanzapine-vs-Ne93TB8mTR
Publisher
Springer Journals
Copyright
Copyright © 2003 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/B:ACLI.0000008171.90644.f8
Publisher site
See Article on Publisher Site

Abstract

Patients with treatment-resistant schizophrenia pose a major challenge to caregivers since only clozapine is documented as having superior efficacy in this population. Although olanzapine is similar to clozapine in structure and receptor profile, it has not been proven to have superior efficacy for this patient group. Nonetheless, olanzapine is being increasingly used in higher doses as clinicians attempt to find a more effective and tolerable therapy for refractory patients. Furthermore, there are little data comparing olanzapine and clozapine in this population. Thirteen patients participated in a randomized double-blind 16-week crossover study of clozapine therapy (450 mg/day) compared to high doses of olanzapine (50 mg/day). No patients on olanzapine responded while 20% responded to clozapine treatment. Olanzapine patients tended to experience higher rates of anticholinergic effects such as dry mouth (80 vs. 20%) and blurry vision (40 vs. 0%). Clozapine-treated patients had higher rates of sialorrhea (80 vs. 10%), sweating (50 vs. 10%), dyspepsia (70 vs. 30%), and lethargy (90 vs. 60%). Neither treatment was associated with significant akathisia. Liver enzyme elevation and lipids were higher with clozapine treatment. Mean weight gain in the initial 8 weeks was 3.4 kg for olanzapine and 1.2 kg for clozapine. High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 11, 2004

References

  • Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
    Beasley, C; Tollefson, G; Tran, P; Satterlee, W; Sanger, T; Hamilton, S
  • Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: Results of an international collaborative trial
    Tollefson, G; Beasley, C; Tran, P; Street, JS; Krueger, JA; Tamura, RN; Graffeo, KA; Thieme, ME
  • Management of treatment-resistant schizophrenia
    Conley, RR; Kelly, DL
  • Novel versus conventional antipsychotic drugs
    Love, RC
  • Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
    Conley, RR; Tamminga, CA; Richardson, CM; Kelly, DL
  • High-dose olanzapine for treatment-refractory schizophrenia
    Sheitman, B; Lindgren, J; Early, J; Sved, M
  • High-dose olanzapine therapy in schizophrenia
    Alao, A; Armenta, WA; Yolles, JC
  • Use of high-dose olanzapine in refractory psychosis
    Reich, J
  • Schizophrenia and schizoaffective disorder treated with high doses of olanzapine
    Fanous, A; Lindenmyer, JP
  • British experience with high-dose olanzapine for treatment-refractory schizophrenia
    Mountjoy, CQ; Baldacchino, AM; Stubbs, JH
  • Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study
    Dursun, SM; Gardner, DM; Bird, DC; Flinn, J
  • Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Volavka, J; Czobor, P; Sheitman, B; Lindenmayer, JP; Citrome, L; McEvoy, JP; Cooper, TB; Chakos, M; Liberman, JA
  • Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia
    Bronson, BD; Lindenmayer, J-P.
  • Optimal dosing of atypical antipsychotics in adults: A review of the current evidence
    Citrome, L; Volavka, J
  • Assessment of Capacity to give consent to research participation: State-of-the-art and beyond
    De Renzo, EG; Conley, RR; Love, RC
  • Improving outcome in schizophrenia: The potential importance of eps and neuroleptic dysphoria
    Gerlach, J
  • Differential olanzapine plasma concentrations by sex in a fixed dose study
    Kelly, DL; Conley, RR; Tamminga, CA
  • Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
    Tollefson, GD; Birkett, MA; Kiesler, GM; Wood, AJ
  • Anticholinergicity and cognitive processing in chronic schizophrenia
    Tracy, JI; Monaco, C; Giovannetti, T; Abraham, G; Josiassen, RC
  • The effects of clozapine, risperi-done, and olanzapine on cognitive function in schizophrenia
    Meltzer, HY; McGurk, SR